Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome Signatures

Inclusion Criteria: * Eighteen years or elder； * Participants underwent enhanced MRI for the evaluation of liver nodules ≤5 cm； * Participants whose platelet count ≥ 50×109/L, prothrombin activity (PTA) ≥ 60%； * Participants who are willing and able to perform hepatectomy or tissure biopsy. Exclusion Criteria: * Participants with different enhancement mode liver nodules that detected by enhanced MRI and without CEUS confirmation； * Diagnosis of malignant tumors before recruitment； * Anti-tumor therapy before recruitment ； * HIV infection； * Pregnancy； * Allogenic blood transfusion or cell therapy within 14 days before peripheral blood samples collection; * Participants with hepatic encephalopathy, hemangioma, ascites, gastrointestinal bleeding, jaundice, liver failure, congestive heart failure, or any other serious diseases that causing organ damage. * Participants with any other factors that may leading to termination of the study.